Evidence map›Paper›PMID 42121011›Full record

ArticleBMC microbiology2026

In vitro and in vivo activity of eravacycline against Mycobacterium abscessus.

Kai Cheng, Haohan Liu, Mingyue Lyu, Yuanyuan Shang, Weicong Ren, Jiaying Guo, Yu Pang, Shanshan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kai Cheng *Department of Pharmacology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Haohan Liu *Department of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Mingyue LyuDepartment of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Yuanyuan ShangDepartment of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Weicong RenDepartment of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Jiaying GuoDepartment of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Yu PangDepartment of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China. pangyupound@163.com.
Shanshan LiDepartment of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China. Lss9011@126.com.

Funding

Beijing Nova Program 20230484295
6 · The paper itself

Abstract

Eravacycline is a fluorocycline antibiotic with activity against multidrug-resistant Gram-negative bacteria. However, its activity against Mycobacterium abscessus (MAB) has not been fully evaluated. This study aimed to evaluate the in vitro and in vivo activity of eravacycline against MAB. The in vitro activity of eravacycline against 73 MAB isolates was evaluated by broth microdilution to determine minimal inhibition concentrations (MICs). For in vivo assessment, a BALB/c nude mouse model was established via intravenous infection with MAB, resulting in systemic dissemination of bacteria. Outcomes were evaluated based on bacterial burden in the lungs and spleens and histopathological analysis. In this study, eravacycline demonstrated low MIC values against MAB isolates, with MIC

Indexed as

Anti-Bacterial AgentsMycobacterium abscessusMycobacterium Infections, NontuberculousTetracyclinesAnimalsBacterial LoadDisease Models, AnimalFemaleHumansLungMiceMice, Inbred BALB CMice, NudeMicrobial Sensitivity TestsSpleenAnti-Bacterial AgentseravacyclineTetracyclinesDrug susceptibilityEravacyclineIn vitroIn vivoMycobacterium abscessus

Identifiers

PMID42121011
PMCPMC13334892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.